We have located links that may give you full text access.
Intravoxel incoherent motion MRI for the differentiation of benign, intermediate, and malignant solid soft-tissue tumors.
Journal of Magnetic Resonance Imaging : JMRI 2017 December
PURPOSE: To determine the diagnostic potential of apparent diffusion coefficient (ADC) and intravoxel incoherent motion (IVIM)-derived parameters for the differentiation of benign, intermediate, and malignant solid soft-tissue tumors.
MATERIALS AND METHODS: The Institutional Review Board approved this prospective study, and informed consent was obtained. IVIM imaging was performed in 64 patients including 44 benign, 6 intermediate, and 14 malignant solid soft-tissue tumors at 1.5T. The IVIM parameters of the soft-tissue tumors were assessed using the Kruskal-Wallis test. The diagnostic performance of the parameters was evaluated using receiver operating characteristic (ROC) analysis.
RESULTS: The ADC and true diffusion coefficient (D) values of malignancies (1.28 ± 0.31, 1.06 ± 0.23 [×10-3 mm2 /sec]) were significantly lower than those of intermediate (1.49 ± 0.54, 1.30 ± 0.50 [×10-3 mm2 /sec]), or benign soft-tissue tumors (1.62 ± 0.37, 1.36 ± 0.33 [×10-3 mm2 /sec]) (P = 0.007 and P = 0.009, respectively). In the differential diagnosis of malignancies from benign tumors, ADC demonstrated the highest area under the curve (Az) value (Az = 0.793). The perfusion fraction (f) values of intermediate soft-tissue tumors (8.41 ± 2.73) were significantly different from those of benign and malignant tumors (14.70 ± 5.37 [P = 0.002]; 14.44 ± 5.31 [P = 0.021]). f showed the highest Az value in differentiating intermediate from benign, and malignant soft-tissue tumors (Az = 0.90, and Az = 0.833, respectively). The pseudodiffusion coefficient (D*) values of malignant soft-tissue tumors (144.40 ± 24.88 [×10-3 mm2 /sec]) were significantly higher than those of benign tumors (124.96 ± 26.24 [×10-3 mm2 /sec]) (P = 0.019).
CONCLUSION: IVIM imaging may be helpful for differentiating benign, intermediate, and malignant solid soft-tissue tumors.
LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2017;46:1611-1618.
MATERIALS AND METHODS: The Institutional Review Board approved this prospective study, and informed consent was obtained. IVIM imaging was performed in 64 patients including 44 benign, 6 intermediate, and 14 malignant solid soft-tissue tumors at 1.5T. The IVIM parameters of the soft-tissue tumors were assessed using the Kruskal-Wallis test. The diagnostic performance of the parameters was evaluated using receiver operating characteristic (ROC) analysis.
RESULTS: The ADC and true diffusion coefficient (D) values of malignancies (1.28 ± 0.31, 1.06 ± 0.23 [×10-3 mm2 /sec]) were significantly lower than those of intermediate (1.49 ± 0.54, 1.30 ± 0.50 [×10-3 mm2 /sec]), or benign soft-tissue tumors (1.62 ± 0.37, 1.36 ± 0.33 [×10-3 mm2 /sec]) (P = 0.007 and P = 0.009, respectively). In the differential diagnosis of malignancies from benign tumors, ADC demonstrated the highest area under the curve (Az) value (Az = 0.793). The perfusion fraction (f) values of intermediate soft-tissue tumors (8.41 ± 2.73) were significantly different from those of benign and malignant tumors (14.70 ± 5.37 [P = 0.002]; 14.44 ± 5.31 [P = 0.021]). f showed the highest Az value in differentiating intermediate from benign, and malignant soft-tissue tumors (Az = 0.90, and Az = 0.833, respectively). The pseudodiffusion coefficient (D*) values of malignant soft-tissue tumors (144.40 ± 24.88 [×10-3 mm2 /sec]) were significantly higher than those of benign tumors (124.96 ± 26.24 [×10-3 mm2 /sec]) (P = 0.019).
CONCLUSION: IVIM imaging may be helpful for differentiating benign, intermediate, and malignant solid soft-tissue tumors.
LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 2 J. Magn. Reson. Imaging 2017;46:1611-1618.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app